Beam Therapeutics stock surged over 10% pre-market after reporting positive early-stage data for its gene-editing therapy BEAM-302. The trial showed the treatment sustained protective protein levels for up to one year in patients with AAT deficiency. Consequently, the company plans to begin a global trial in the second half of 2026.